

Inhibitors

Screening Libraries

Proteins

Product Data Sheet

GLP-2(rat) (Ala-13C₃,15N)

Cat. No.: HY-P1142S

Molecular Formula: $\mathsf{C_{_{163}}^{_{13}}} \mathsf{C_{_{3}}} \mathsf{H_{_{256}}} \mathsf{N_{_{43}}^{_{15}}} \mathsf{NO_{_{56}}} \mathsf{S}$

Molecular Weight: 3800.11

Sequence: His-{Ala-13C3,15N}-Asp-Gly-Ser-Phe-Ser-Asp-Glu-Met-Asn-Thr-Ile-Leu-Asp-Asn-Leu-Al

a-Thr-Arg-Asp-Phe-Ile-Asn-Trp-Leu-Ile-Gln-Thr-Lys-Ile-Thr-Asp

H-{Ala-13C3,15N}-DGSFSDEMNTILDNLATRDFINWLIQTKITD Sequence Shortening:

Target: Isotope-Labeled Compounds

Others Pathway:

Storage: Please store the product under the recommended conditions in the Certificate of

Analysis.

BIOLOGICAL ACTIVITY

Description	GLP-2(rat) (Ala- 13 C3, 15 N) is 13 C and 15 N labeled GLP-2(rat) (HY-P1142). GLP-2(rat) is an intestinal growth factor. GLP-2(rat) stimulates cell proliferation and inhibits apoptosis. GLP-2(rat) enhances mucosal mass and function in residual small intestine after massive small bowel resection (MSBR).
In Vitro	Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-216.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA

Page 1 of 1